Genetic Factors in Allergic Contact Dermatitis Explained

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on skin & immune health. Browse all Skin & Immune Health education

Allergic contact dermatitis is one of the most common reasons people see a dermatologist, yet two people exposed to the same nickel earring, fragrance, or hair dye can have completely different reactions. Part of that difference is written in your genes. Understanding the genetic factors behind allergic contact dermatitis can help you make sense of stubborn, recurring rashes and have a more productive conversation with a qualified provider.

What allergic contact dermatitis actually is

Allergic contact dermatitis (ACD) is a delayed, type IV immune reaction. Small chemical molecules called haptens penetrate the skin, bind to your own proteins, and are then flagged by T cells as foreign. On re-exposure, the immune system mounts an inflammatory response — the redness, itching, and blistering of a contact rash. Common triggers include nickel, fragrances, preservatives, rubber accelerators, and paraphenylenediamine (PPD) in hair dye. This is distinct from irritant contact dermatitis, which is direct chemical damage rather than an immune-driven allergy.

Skin barrier genetics: the FLG gene

The single most studied genetic factor in contact dermatitis is FLG, the gene that codes for filaggrin. Filaggrin is a structural protein that helps bundle skin cells into a tight, water-retaining barrier. Loss-of-function variants in FLG (such as R501X and 2282del4) reduce filaggrin and leave the skin barrier more permeable. A leakier barrier lets more haptens reach immune cells in the deeper skin, which research associates with a higher likelihood of sensitization. FLG variants are best known for their link to atopic dermatitis (eczema), and that same barrier weakness is relevant to contact allergy.

Detoxification and hapten handling: NAT2, GSTM1, and GSTT1

Your skin also metabolizes the chemicals it encounters. NAT2 (N-acetyltransferase 2) governs how quickly you acetylate certain aromatic amines, including the reactive intermediates formed from PPD hair dye. So-called slow-acetylator NAT2 genotypes have been studied in the context of dye sensitivity. The glutathione S-transferase genes GSTM1 and GSTT1 help neutralize reactive compounds; common null variants (where the gene is entirely absent) reduce this detox capacity and have been examined in nickel and chromium contact allergy. These genes sit in the detoxification and inflammation pathways your body uses every day.

What the research shows

Population and twin studies suggest contact allergy has a meaningful heritable component, with immune and barrier genes both contributing. Filaggrin deficiency is a well-replicated risk factor for impaired skin barrier function. Studies of detoxification genotypes report associations with specific allergens rather than a single universal effect — genetics shift the odds, they do not decide the outcome. Environmental exposure, dose, skin site, and how often you contact a substance still matter enormously.

Understanding your triggers versus managing them

Genetic insight explains susceptibility; it does not replace clinical care. Identifying your actual triggers is done through patch testing ordered by a dermatologist, not through a genetic test. Once triggers are known, evidence-based management centers on allergen avoidance, gentle barrier-supporting skincare, and treatments your provider recommends. Knowing you carry a barrier or detox variant can be a useful reason to be more diligent about reading ingredient labels and protecting your skin.

Where pathway-level genetic insight fits

Genetics is a guide, not a guarantee. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across systems such as inflammation and detoxification — the same broad pathways that shape how your skin responds to the world. It offers pathway-level context about your biology, not a diagnosis of any skin condition. As the governing principle goes: PlexusDx tells you about your biology; it does not tell you what to put in your body.

Curious how your DNA shapes the pathways behind your biology? The Precision Peptide Genetic Test gives you pathway-level genetic context to bring to an informed conversation with your provider — because when it comes to your health, it is better to know than to guess.

Frequently Asked Questions

Is allergic contact dermatitis genetic?

Contact dermatitis has a genetic component, but it is not purely inherited. Variants in barrier genes like FLG and detoxification genes such as GSTM1 and NAT2 can raise susceptibility, yet exposure to the specific allergen is still required. Genetics shifts your odds; it does not guarantee a reaction will occur.

Can a genetic test tell me what I am allergic to?

No. Identifying specific contact allergens requires patch testing ordered by a dermatologist. Genetic testing offers pathway-level context about barrier and detoxification biology, not a list of your triggers. The two are complementary but different tools, and a provider interprets patch results for your care.

Does having an FLG variant mean I will get dermatitis?

Not necessarily. FLG loss-of-function variants weaken the skin barrier and are associated with higher risk, but many carriers never develop significant dermatitis. A variant is a map of tendencies, not a verdict. Barrier-supportive skincare and avoiding known irritants can meaningfully reduce day-to-day impact.

How is this different from eczema?

Eczema (atopic dermatitis) is a chronic inflammatory condition often tied to the same FLG barrier genes, while allergic contact dermatitis is an immune reaction to a specific external chemical. They can overlap and share barrier biology, but their triggers differ. A qualified provider can distinguish them and guide management.

This article is part of the PlexusDx Education Hub. Browse all Skin & Immune Health education

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not diagnose, treat, cure, or prevent any disease, and it does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before making decisions about your health or beginning any peptide protocol.